

30.03.2022

<b>11:30 - 13:00</b>	<b>Mirati Therapeutics, Inc. - Tailoring therapy: Emerging treatment options in NSCLC</b>	<b>Forum Hall</b>
----------------------	---	-------------------

11:30 - 11:35 **Welcome and introductions**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

11:35 - 11:55 **The evolving landscape of advanced NSCLC therapy**

R. Juergens, JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA

11:55 - 12:15 **Addressing resistance to checkpoint inhibitors in NSCLC**

F. Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

12:15 - 12:35 **Targeting KRAS-driven NSCLC**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

12:35 - 13:00 **Q&A and summary**

**11:30 - 13:00 Amgen - Targeting KRASG12C: A new era for patients with advanced NSCLC South Hall 2**

**11:30 - 11:35 Welcome and introduction**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

**11:35 - 11:50 KRASG12C inhibition: A major landmark in 2nd line treatment of patients with advanced NSCLC**

J. De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

**11:50 - 12:05 The turning point: Practical considerations when emerging biomarkers become actionable**

K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

**12:05 - 12:20 Forward thinking: Future perspectives in targeting KRAS in NSCLC**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

**12:20 - 12:35 Managing patients with KRAS G12C-mutant NSCLC: Real-world perspectives**

K. Kerr<sup>1</sup>, S. Peters<sup>2</sup>, J. De Langen<sup>3</sup>, <sup>1</sup>Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, <sup>2</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, <sup>3</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

**12:35 - 12:55 Live Q&A / discussion**

**12:55 - 13:00 Summary and close**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

**13:45 - 14:15 Heine Hansen Award ELCC 2022 Congress Hall**

**13:45 - 13:50 Introduction**

**13:50 - 14:15 Heine Hansen Award ELCC 2022**

<b>14:30 - 16:00</b>	<b>What to do after immunotherapy failure and when to avoid immunotherapy in early disease NSCLC</b>	<b>Congress Hall</b>
	Moderation: R.S. Herbst, Medical Oncology Department, Yale University School of Medicine, New heaven, US	
14:30 - 14:40	<b>Case presentation</b>	
14:40 - 14:55	<b>What is the role of chemotherapy and antiangiogenics?</b>	
	<u>R.S. Herbst</u> , Yale University School of Medicine, New heaven, US	
14:55 - 15:10	<b>IO rechallenge</b>	
	<u>B. Piet</u> , Radboud University Medical Center, Nijmegen, NL	
15:10 - 15:25	<b>What to do after failure of immunotherapy in early disease?</b>	
15:25 - 15:40	<b>Novel approaches</b>	
	<u>J. Zugazagoitia</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
15:40 - 16:00	<b>Discussion</b>	
<b>14:30 - 16:00</b>	<b>Not so small anymore: New therapies and cutting-edge science to guide the care of patients with small cell lung cancer</b>	<b>Forum Hall</b>
	Moderation: J. Naidoo, Oncology Dept., Beaumont Hospital, Dublin, IE	
14:30 - 14:50	<b>First shot on goal is the most important: Updates on first line therapy for limited stage and extensive stage SCLC</b>	
	<u>J. Naidoo</u> , Beaumont Hospital, Dublin, IE	
14:50 - 15:10	<b>Battling recurrent SCLC: Emerging therapies for platinum refractory disease</b>	
	<u>G. Lo Russo</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
15:10 - 15:30	<b>Delivering on the promise of precision medicine in SCLC: Emerging molecular sub-types</b>	
	<u>B. Drapkin</u> , UT Southwestern Medical Center, Dallas, US	
15:30 - 15:50	<b>Transformed SCLC: Emerging science on histologic subtype switching</b>	
	<u>T. Sen</u> , Memorial Sloan Kettering Cancer Center, New York, US	
15:50 - 16:00	<b>Q&amp;A</b>	

<b>14:30 - 16:00</b>	<b>Implementation of screening programs in Europe</b>	<b>South Hall 2</b>
14:30 - 14:50	<b>Where do we stand?</b> <u>M. Oudkerk</u> , University of Groningen, Groningen, NL	
14:50 - 15:10	<b>Reading guidelines</b> <u>N. Bogot</u> , Shaare Zedek Medical Center, Jerusalem, IL	
15:10 - 15:30	<b>Nodule investigation</b> <u>D.R. Baldwin</u> , City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB	
15:30 - 15:50	<b>Biomarkers in screening effort</b> <u>L. Montuenga</u> , Clinica Universidad de Navarra, Pamplona, ES	
15:50 - 16:00	<b>Q&amp;A</b>	
<b>16:30 - 18:00</b>	<b>Thymic tumours</b> Moderation: E. Ruffini <sup>1</sup> , N. Girard <sup>2</sup> , <sup>1</sup> Thoracic Surgery, University of Turin, Torino, IT, <sup>2</sup> Thorax Institute, Institut Curie, Paris, FR	<b>Congress Hall</b>
16:30 - 16:50	<b>Update on the Staging Project for the 9th edition of the TNM staging system of thymic tumors</b> <u>E. Ruffini</u> , University of Turin, Torino, IT	
16:50 - 17:10	<b>Early-stage tumors: What is the optimal surgical management in 2022?</b> <u>V. Fang</u> , Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN	
17:10 - 17:30	<b>Locally advanced tumors: The key word is multidisciplinary</b> <u>A. Rimner</u> , Memorial Sloan Kettering Cancer Center, New York, US	
17:30 - 17:50	<b>Advanced tumors, new frontiers: Promising results?</b> <u>N. Girard</u> , Institut Curie, Paris, FR	
17:50 - 18:00	<b>Q&amp;A</b>	

<b>16:30 - 18:00</b>	<b>New insights in the treatment of geriatric patients</b>	<b>South Hall 2</b>
	Moderation: L. Decoster, Department Of Medical Oncology, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE	
16:30 - 16:50	<b>Biological hallmarks of ageing: potential therapeutic targets?</b>	
	<u>R. Ferrara</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
16:50 - 17:10	<b>Geriatric assessment in the chest MDT</b>	
	<u>L. Decoster</u> , UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE	
17:10 - 17:30	<b>Can AI help guide diagnosis and treatment of special cancer populations such as the elderly?</b>	
	<u>A. Dekker</u> , Maastrro Clinic, Maastricht, NL	
17:30 - 17:50	<b>What past and future trials tell us</b>	
	<u>R. Corre</u> , CH de Cornouaille - Hopital Laennec, Quimper, FR	
17:50 - 18:00	<b>Q&amp;A</b>	
<b>16:30 - 18:00</b>	<b>Proffered Paper session 1</b>	<b>Forum Hall</b>
<b>18:15 - 19:45</b>	<b>Bristol Myers Squibb - Breaking barriers in thoracic cancers: The expanding possibilities for patients with I-O treatment</b>	<b>Forum Hall</b>
18:15 - 18:18	<b>Welcome &amp; introductions</b>	
	<u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
18:18 - 18:25	<b>Is I-O treatment redefining survival for thoracic cancers?</b>	
	<u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
18:25 - 18:45	<b>The shifting treatment paradigm with I-O in resectable NSCLC</b>	
	<u>P. Forde</u> , Johns Hopkins University, Baltimore, US	
18:45 - 19:10	<b>Understanding the potential for long-term survival with I-O in metastatic NSCLC</b>	
	<u>N. Reinmuth</u> , Asklepios-Fachklinikum, Gauting, DE	
19:10 - 19:30	<b>I-O as a new standard for patients with unresectable MPM</b>	
	<u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
19:30 - 19:45	<b>Closing remarks &amp; live Q&amp;A</b>	
	<u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	

<b>18:15 - 19:45</b>	<b>Takeda - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications</b>	<b>South Hall 2</b>
18:15 - 18:20	<b>Welcome and introduction</b> <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
18:20 - 18:35	<b>Precision medicine in NSCLC: From biomarker testing to therapy selection</b> <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
18:35 - 19:00	<b>Emerging therapies for advanced NSCLC With EGFR Exon 20 insertion mutations: Developments and implications</b> <u>M. Pérol</u> , Centre Léon Bérard, Lyon, FR	
19:00 - 19:25	<b>Frontline treatment of ALK-Positive NSCLC: Therapy considerations and selection</b> <u>S. Popat</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
19:25 - 19:43	<b>Live Q&amp;A / discussion</b>	
19:43 - 19:45	<b>Concluding remarks</b> <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	

31.03.2022

**08:00 - 09:00 Oligoprogression in Advanced NSCLC** **Congress Hall**  
Moderation: F. McDonald, The Royal Marsden Hospital - Chelsea, London, GB

08:00 - 08:15 **Presentation of case: Defining oligo-progression**  
M. Guckenberger, Universitätsspital Zürich, Zürich, CH

08:15 - 08:30 **Is there a role for SBRT in Oligo-progression?**  
F. McDonald, The Royal Marsden Hospital - Chelsea, London, GB

08:30 - 08:45 **Is there biological rationale for local approaches in oligo-progressive systemic disease?**  
L. Sequist, Massachusetts General Hospital, Boston, US

08:45 - 09:00 **Discussion**

**08:00 - 09:00 Surgery vs radiation therapy for stage III NSCLC in the context of immunotherapy** **Forum Hall**  
Moderation: K. Oselin, Chemotherapy Department, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

08:00 - 08:10 **Introduction and first vote**  
K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

08:10 - 08:30 **Surgical perspective on neoadjuvant immunotherapy for resectable stage III non-small cell lung cancer**  
A. Brunelli, St. James's University Hospital, Leeds, GB

08:30 - 08:50 **Radiotherapy perspective for resectable stage III non-small cell lung cancer in the era of immunotherapy**  
C. Faivre-Finn, The Christie NHS Foundation Trust, Manchester, GB

08:50 - 09:00 **Second vote and conclusions**  
K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

**08:00 - 09:00 YO session 1** **South Hall 2**



<b>09:15 - 10:45</b>	<b>Minimal residual disease, biological disease</b>	<b>Forum Hall</b>
	Moderation: C. Abbosh, UCL - University College London, London, GB	
09:15 - 09:35	<b>How to assess MRD in NSCLC?</b>	
	<u>C. Abbosh</u> , UCL - University College London, London, GB	
09:35 - 09:55	<b>How MRD correlates with imaging in NSCLC?</b>	
	<u>F. Grossi</u> , University of Insubria, Busto Arsizio, IT	
09:55 - 10:15	<b>MRD as a predictor of survival in NSCLC</b>	
	<u>P. Hofman</u> , CHU Nice - Hopital Pasteur, Nice, FR	
10:15 - 10:35	<b>How to design clinical trials integrating MRD?</b>	
	<u>S. Gadgeel</u> , Henry Ford Cancer Institute - Henry Ford Hospital, Detroit, US	
10:35 - 10:45	<b>Q&amp;A</b>	
<b>09:15 - 10:45</b>	<b>Telemedicine in lung cancer: What to do in 2022?</b>	<b>South Hall 2</b>
	Moderation: N. Leighl, Medical Oncology Department, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
09:15 - 09:35	<b>Improving outcome through electronic surveillance</b>	
	<u>F. Denis</u> , ILC Jean Bernard, Le Mans, FR	
09:35 - 09:55	<b>Applications of telehealth in lung cancer</b>	
	<u>M. O'Cathail</u> , Nottingham City Hospital, Nottingham, GB	
09:55 - 10:15	<b>Telescreening, here we come!</b>	
	<u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
10:15 - 10:35	<b>Improving clinical trials reporting through telemedicine</b>	
	<u>L. Coate</u> , University Hospital Limerick, Limerick, IE	
10:35 - 10:45	<b>Q&amp;A</b>	



09:15 - 10:45	<b>ESMO Colloquium supported by Eli Lilly and company - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR</b>	<b>Congress Hall</b>
09:15 - 09:25	<b>Introduction</b>	
09:25 - 09:45	<b>Tissue testing for actionable biomarkers in patients with advanced NSCLC: Scientific and implementation perspectives and the positioning of molecular tumour boards</b> <u>F. Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
09:45 - 10:05	<b>An overview of molecular epidemiology of rare molecular aberrations and matching treatment strategies for patients with non-EGFR, oncogene-addicted advanced NSCLC</b> <u>F. Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
10:05 - 10:25	<b>RET-fused NSCLC: State of the art treatment of advanced disease, including sanctuary sites</b> <u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
10:25 - 10:40	<b>Q&amp;A and live discussion</b>	
10:40 - 10:45	<b>Concluding remarks</b> <u>F. Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, ES	

<b>11:15 - 12:45</b>	<b>Personalized treatment of lung cancer brain metastases</b>	<b>Congress Hall</b>
	Moderation: J. Remon Masip <sup>1</sup> , L. Hendriks <sup>2</sup> , <sup>1</sup> Dept. Oncology, HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES, <sup>2</sup> Pulmonary Diseases Department, Maastricht University Medical Center (MUMC), Maastricht, NL	
11:15 - 11:25	<b>Case presentation - A patient with driver mutation</b>	
	<u>A. Levy</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
11:25 - 11:40	<b>TKI in patients with oncogene driven NSCLC</b>	
	<u>J. Remon Masip</u> , HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES	
11:40 - 11:55	<b>Immunotherapy for non-oncogene addicted NSCLC</b>	
	<u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
11:55 - 12:10	<b>Sequencing of radiotherapy and systemic therapy</b>	
	<u>A. Levy</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
12:10 - 12:25	<b>When to incorporate surgery in the treatment of lung cancer brain metastases?</b>	
12:25 - 12:45	<b>Discussion</b>	
<b>11:15 - 12:45</b>	<b>First line in non-oncogene addicted NSCLC</b>	<b>Forum Hall</b>
	Moderation: J. Feliciano, Johns Hopkins Hospital, Baltimore, US	
11:15 - 11:35	<b>Biomarker testing (tissue, blood) for non-oncogenic addicted NSCLC</b>	
	<u>T. Stinchcombe</u> , Duke Cancer Center, Durham, US	
11:35 - 11:55	<b>First line therapy in non-oncogene addicted NSCLC</b>	
	<u>M. Pérol</u> , Centre Léon Bérard, Lyon, FR	
11:55 - 12:15	<b>Resistance to therapy in non-oncogene addicted NSCLC</b>	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
12:15 - 12:35	<b>Long term needs and survivorship needs in advanced NSCLC</b>	
	<u>J. Feliciano</u> , Johns Hopkins Hospital, Baltimore, US	
12:35 - 12:45	<b>Q&amp;A</b>	

11:15 - 12:45	<b>More targets, more drugs, more choices, more conflicts</b> Moderation: K. Kerr, Department Of Pathology, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB	<b>South Hall 2</b>
11:15 - 11:25	<b>Case presentation - A patient with ALK+ NSCLC: How clinical characteristics, biopsy specimen and cfDNA can guide treatment decisions</b> <u>L. Mezquita</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
11:25 - 11:40	<b>Integrated testing: The challenges we now face</b> <u>K. Kerr</u> , Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB	
11:40 - 11:55	<b>Targeted therapy and immunotherapy: Can the patient have both?</b> <u>A.-M. Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
11:55 - 12:10	<b>Co-mutations: Impact on current treatments and new combinations</b> <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
12:10 - 12:25	<b>Rebiopsy and cfDNA in a complex and changing landscape</b> <u>N. Normanno</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
12:25 - 12:45	<b>Discussion</b>	
13:30 - 15:00	<b>Janssen Oncology - Evolving treatment options and practices in EGFR-mutant NSCLC</b>	<b>Forum Hall</b>
13:30 - 15:00	<b>AstraZeneca - CNS disease management in EGFRm NSCLC</b>	<b>South Hall 2</b>
15:10 - 16:40	<b>Proffered Paper session 2</b>	<b>Congress Hall</b>
17:00 - 18:00	<b>Salvage surgery and RT</b>	<b>Congress Hall</b>
17:00 - 17:15	<b>Presentation of case</b> <u>C. Le Pechoux</u> , Institut Gustave Roussy, Villejuif, FR	
17:15 - 17:30	<b>Surgery</b> <u>P. Van Schil</u> , UZA - University Hospital Antwerp, Edegem, BE	
17:30 - 17:45	<b>Radiotherapy</b> <u>D. De Ruysscher</u> , Maastric Clinic, Maastricht, NL	
17:45 - 18:05	<b>Discussion</b>	

<b>17:00 - 18:00</b>	<b>New TNM classification: Anatomical vs biological</b>	<b>Forum Hall</b>
	Moderation: V. Rusch, Memorial Sloan Kettering Cancer Center, New York, US	
17:00 - 17:10	<b>Introduction and first vote</b>	
	<u>V. Rusch</u> , Memorial Sloan Kettering Cancer Center, New York, US	
17:10 - 17:30	<b>Anatomical TNM</b>	
	<u>R. Rami-Porta</u> , Hospital Mutua de Terrassa, Terrassa, ES	
17:30 - 17:50	<b>Biological TNM</b>	
	<u>R. Osarogiagbon</u> , Baptist Cancer Center, Memphis, US	
17:50 - 18:00	<b>Second vote and conclusions</b>	
	<u>V. Rusch</u> , Memorial Sloan Kettering Cancer Center, New York, US	
<b>17:00 - 18:00</b>	<b>Mini Oral session 1</b>	<b>South Hall 2</b>
<b>18:15 - 19:45</b>	<b>Novartis</b>	<b>Forum Hall</b>
<b>18:15 - 19:45</b>	<b>Thermo Fisher Scientific</b>	<b>South Hall 2</b>

01.04.2022

**08:15 - 09:15 Sublobar resection versus lobectomy** **Forum Hall**  
Moderation: E. Lim, Royal Brompton Hospital, London, GB

08:15 - 08:25 **Introduction and first vote**  
E. Lim, Royal Brompton Hospital, London, GB

08:25 - 08:45 **Sublobar**

08:45 - 09:05 **Lobectomy**  
A. Verhagen, Radboud University Medical Center, Nijmegen, NL

09:05 - 09:15 **Second vote and conclusions**  
E. Lim, Royal Brompton Hospital, London, GB

<b>08:15 - 09:15</b>	<b>Mini Oral session 2</b>	<b>Congress Hall</b>
<b>08:15 - 09:15</b>	<b>YO session 2</b>	<b>South Hall 2</b>
<b>08:30 - 10:00</b>	<b>EONS session 1</b>	<b>Club A</b>
<b>09:30 - 10:00</b>	<b>Lung cancer in 2030</b>	<b>Congress Hall</b>

09:30 - 09:35 **Introduction**

09:35 - 10:00 **Lung cancer in 2030**  
P. Jänne, Dana Farber Cancer Institute, Boston, US

10:30 - 12:00 New roads in I-O		Congress Hall
10:30 - 10:50	<b>A second life for vaccines?</b> <u>L. Bazhenova</u> , Moores Cancer Center - UC San Diego Health, La Jolla, US	
10:50 - 11:10	<b>Playing with checkpoints</b> <u>M. Maio</u> , AOU Senese - Santa Maria delle Scotte, Siena, IT	
11:10 - 11:30	<b>Rethinking cytokines</b> <u>E. Garon</u> , UCLA Hematology/Oncology Santa Monica, Santa Monica, US	
11:30 - 11:50	<b>Personalizing T-cell therapies</b> <u>B. Creelan</u> , H. Lee Moffitt Cancer Center University of South Florida, Tampa, US	
11:50 - 12:00	<b>Q&amp;A</b>	
10:30 - 12:00 Perioperative strategies: ICI, TKIs, adjuvant, neoadjuvant		Forum Hall
	Moderation: E. Felip, Medical Oncology Service (lung Cancer Unit) , Vall d'Hebron University Hospital, Barcelona, ES	
10:30 - 10:50	<b>Choosing the best endpoints and surrogates for perioperative strategies in NSCLC</b> <u>H. Wakelee</u> , Stanford University, Stanford, US	
10:50 - 11:10	<b>(Neo)Adjuvant TKIs in oncogene addicted tumors</b> <u>P. Forde</u> , St James's Hospital, Dublin, IE	
11:10 - 11:30	<b>Opportunities and pitfalls of Adjuvant Immunotherapy in resected NSCLC</b> <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:30 - 11:50	<b>Opportunities and pitfalls of Neoadjuvant Immunotherapy in resectable NSCLC</b> <u>T. Cascone</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
11:50 - 12:00	<b>Q&amp;A</b>	

**10:30 - 12:00 How to use real-world evidence for clinical decision making South Hall 2**

- 10:30 - 10:50 **Real-world data: Methodology**  
E. Van De Garde, UMC - University Medical Center Utrecht, Utrecht, NL
- 10:50 - 11:10 **Relevance of real-world data in thoracic oncology**  
S. Ekman, Karolinska University Hospital-Solna, Solna, SE
- 11:10 - 11:30 **Artificial intelligence to manage large set of data in thoracic oncology**  
M. Del Re, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT
- 11:30 - 11:50 **Deconvolution of big data sets in thoracic oncology**  
V. Pancaldi, IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR
- 11:50 - 12:00 **Q&A**

**10:30 - 12:00 EONS session 2 Club A**

**12:45 - 14:15 AstraZeneca - Unresectable stage III NSCLC: No patients left behind Forum Hall**

**12:45 - 14:15 Novocure - TTFields: A potential innovative treatment modality in lung cancer South Hall 2**

Moderation: F. Barlesi<sup>1</sup>, L. Petruzelka<sup>2</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Oncology Department, Charles University - First Faculty of Medicine, Prague, CZ

- 12:45 - 12:50 **Welcome & Objectives**
- 12:50 - 13:10 **What are TTFields - Mechanism of action and experiences in solid tumors**  
M. Proescholdt, UKR - University Hospital Regensburg, Regensburg, DE
- 13:10 - 13:30 **TTFields in malignant pleural mesothelioma (MPM) - The STELLAR trial**  
G.L. Ceresoli, Saronno Hospital, Saronno, IT
- 13:30 - 13:50 **TTFields: A potential innovative treatment modality in lung cancer - The LUNAR trial and beyond**  
M. Cobo Dols, Biomedical Research Institute of Málaga (IBIMA), Malaga, ES
- 13:50 - 14:15 **Live Q&A / discussion**

**12:45 - 14:15 LuCE session 1 Club A**



**14:30 - 15:00 Value of pathological response as an endpoint Congress Hall**

14:30 - 14:35 **Introduction**

14:35 - 15:00 **Value of pathological response as an endpoint**

**15:10 - 16:40 EGFR, Exon 20 and ALK Congress Hall**

Moderation: T.S.K. Mok, Clinical Oncology Department, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

15:10 - 15:30 **Molecular mechanisms and approaches to treating resistance to first line osimertinib in EGFR-mutant lung cancer**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

15:30 - 15:50 **EGFR exon 20 insertions: Science and emerging therapies**

A. Addeo, HUG - Hopitaux Universitaires de Geneve, Geneva, CH

15:50 - 16:10 **Other uncommon EGFR mutations: Strategies in management**

G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

16:10 - 16:30 **Updates on ALK: TKIs and beyond**

M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

16:30 - 16:40 **Q&A**

<b>15:10 - 16:40</b>	<b>How to tackle synchronous oligometastases</b>	<b>Forum Hall</b>
	Moderation: L. Backhus, Stanford University, Stanford, US	
15:10 - 15:30	<b>Surveillance and detection</b>	
	<u>A.D.L. Sihoe</u> , The University of Hong Kong, Hong Kong, HK	
15:30 - 15:50	<b>Role of surgery</b>	
	<u>L. Backhus</u> , Stanford University, Stanford, US	
15:50 - 16:10	<b>Role of radiotherapy</b>	
	<u>S. Senan</u> , Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL	
16:10 - 16:30	<b>Integrative treatment strategies and maintenance therapy</b>	
	<u>S. Padda</u> , Cedars-Sinai Medical Center, Los Angeles, US	
16:30 - 16:40	<b>Q&amp;A</b>	
<b>15:10 - 16:40</b>	<b>Long terms responders</b>	<b>South Hall 2</b>
	Moderation: W. Theelen <sup>1</sup> , S. Pilotto <sup>2</sup> , <sup>1</sup> Thoracic Oncology Dept, Netherlands Cancer Institute, Amsterdam, NL, <sup>2</sup> Medical Oncology Department, University of Verona, Verona, IT	
15:10 - 15:10	<b>Oligometastatic NSCLC: Who benefits the most?</b>	
	<u>W. Theelen</u> , Netherlands Cancer Institute, Amsterdam, NL	
15:10 - 15:10	<b>Long term responders to chemotherapy / antiangiogenics</b>	
	<u>S. Pilotto</u> , University of Verona, Verona, IT	
15:10 - 15:30	<b>Long term responders to TKIs in oncogene-addicted NSCLC</b>	
	<u>R. Dziadziuszko</u> , Medical University of Gdansk, Gdansk, PL	
15:30 - 15:50	<b>Long term responders to immune checkpoint inhibitors</b>	
	<u>T. Leal</u> , Emory University, Atlanta, US	
15:50 - 16:00	<b>Q&amp;A</b>	
<b>15:10 - 16:40</b>	<b>LuCE session 2</b>	<b>Club A</b>

**17:00 - 18:30 Oncogene addicted tumours, KRAS, RET, HER2, BRAF Congress Hall**  
Moderation: L. Mezquita, Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

17:00 - 17:20 **METex14**  
L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

17:20 - 17:40 **New drugs targeting RET**  
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

17:40 - 18:00 **New drugs targeting HER2**  
J. Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR

18:00 - 18:20 **New drugs targeting BRAF**  
D. Planchard, Institut Gustave Roussy, Villejuif, FR

18:20 - 18:30 **Q&A**

**17:00 - 18:30 Covid 19, vaccines and management of patients outside the pandemic Forum Hall**

17:00 - 17:20 **Antibody-dependent immune response in cancer patients**  
B. Halmos, Montefiore Medical Center, New York City, US

17:20 - 17:40 **Neutralizing responses in cancer patients and variants**  
M. Obeid, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

17:40 - 18:00 **COVID-19 and cancer, now and later perspectives in US**  
N. Duma, Mayo Clinic, Rochester, US

18:00 - 18:20 **COVID-19 and lung cancer, management outside of the pandemic**  
M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

18:20 - 18:30 **Q&A**

<b>17:00 - 18:30</b>	<b>Scientific advances in malignant pleural mesothelioma</b>	<b>South Hall 2</b>
	Moderation: N. Reguart Aransay, Dept. Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
17:00 - 17:20	<b>Updates in the biology of malignant mesothelioma</b>	
	<u>P. Bironzo</u> , Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT	
17:20 - 17:40	<b>Surgery for malignant mesothelioma for which patient?</b>	
	<u>I. Opitz</u> , University Hospital Zürich, Zurich, CH	
17:40 - 18:00	<b>Role of radical radiotherapy</b>	
	<u>M. De Perrot</u> , Princess Margaret Cancer Centre, Toronto, CA	
18:00 - 18:20	<b>Systemic treatment: Where are we now and where are we heading?</b>	
	<u>N. Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
18:20 - 18:30	<b>Q&amp;A</b>	
<b>18:45 - 20:15</b>	<b>Sanofi Genzyme - Quantity versus quality of life in advanced NSCLC patients treated with immunotherapy</b>	<b>Forum Hall</b>
<b>18:45 - 20:15</b>	<b>MSD - Evolving immuno-oncology treatment paradigm in NSCLC</b>	<b>South Hall 2</b>

02.04.2022

**08:30 - 10:00 AI-enabled analysis of big data for optimising cancer patient management: A glimpse to the horizon** **Forum Hall**  
Moderation: A. Scarpa, Arc-net Research Centre - Dept. Diagnostics & Public Health, Ospedale Universitario Verona, Verona, IT

08:30 - 08:50 **Current practice and emerging breakthroughs in AI empowered pathology and genomics**  
A. Scarpa, Ospedale Universitario Verona, Verona, IT

08:50 - 09:10 **Current practice and emerging breakthroughs in AI-imaging/radiomics**  
Z. Bodalal, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

09:10 - 09:30 **Current practice and emerging breakthroughs in AI-enabled oncology drug development**

09:30 - 09:50 **Man and machine: An uneasy pair in multiparametric decision making?**  
N. Paragios, CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR

09:50 - 10:00 **Q&A**

**08:30 - 10:00 Treatment sequencing after first-line immunotherapy** **South Hall 2**

08:30 - 08:50 **Standard of care in immuno-pretreated NSCLC**  
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

08:50 - 09:10 **Mechanisms of resistance to immunotherapy**  
P. Nisticò, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

09:10 - 09:30 **New drugs for immuno-pretreated NSCLC**  
M.R. Garcia Campelo, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

09:30 - 09:50 **Potentiality of CAR-T in lung cancer**  
P. Adusumilli, Memorial Sloan Kettering Cancer Center, New York, US

09:50 - 10:00 **Q&A**

<b>10:15 - 11:45</b>	<b>Duration of IO: Limited vs forever</b>	<b>Forum Hall</b>
10:15 - 10:25	<b>Introduction and first vote</b>	
	<u>S. Ramalingam</u> , Winship Cancer Institute of Emory University, Atlanta, US	
10:25 - 10:45	<b>Limited</b>	
	<u>B. Besse</u> , Institut Gustave Roussy, Villejuif, FR	
10:45 - 11:05	<b>Forever</b>	
	<u>H. Linardou</u> , Metropolitan Hospital, Athens, GR	
11:05 - 11:15	<b>Second vote and conclusions</b>	
	<u>S. Ramalingam</u> , Winship Cancer Institute of Emory University, Atlanta, US	
<b>10:15 - 11:45</b>	<b>KRAS: Finally druggable?</b>	<b>South Hall 2</b>
	Moderation: C. Lindsay, Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, GB	
10:15 - 10:35	<b>RAS G12C</b>	
	<u>J. Menis</u> , AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT	
10:35 - 10:55	<b>Novel agents (RAS-ON inhibitors, siRNAs, etc.)</b>	
	<u>M. Awad</u> , Dana Farber Cancer Institute, Boston, US	
10:55 - 11:15	<b>Combination KRAS with ICI</b>	
	<u>A. Sacher</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
11:15 - 11:35	<b>Co-mutations</b>	
	<u>C. Lindsay</u> , The Christie NHS Foundation Trust, Manchester, GB	
11:35 - 11:45	<b>Q&amp;A</b>	